To the Editor: In his article on the relationship between doctors and the pharmaceutical industry, Mitchell highlights moves to bring about greater transparency.1 While such moves are important, they do not go nearly far enough.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Monash Medical Centre, Clayton, VIC.
Correspondence: barnino@gmail.com
- 1. Mitchell PB. Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry. Med J Aust 2009; 191: 273-275. <MJA full text>
- 2. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569-1582.
- 3. Association of American Medical Colleges. Industry funding of medical education. Report of an AAMC Task Force. Washington, DC: AAMC, 2008: 1-34. http://services.aamc.org/publications/showfile.cfm?file=version114.pdf&prd_id=232 (accessed Jan 2010).
Online responses are no longer available. Please refer to our instructions for authors page for more information.